Biogen And Isis Strengthen Their Bond Through Third Tie-Up
This article was originally published in The Pink Sheet Daily
Biogen and Isis make their third tie-up this year, this time for collaboration on the discovery of drugs for neurodegenerative diseases.
You may also be interested in...
Biogen Idec reported steady progress in the clinic for four late-stage programs, including hemophilia. Recent bumps include a three-month delay for the MS product BG-12, but nothing that would derail its Phase III pipeline.
FDA’s Metabolic and Endocrinologic Advisory Committee votes 9 to 6 in favor of Genzyme’s mipomersen for homozygous familial hypercholesterolemia Oct. 18.
The two companies build on an existing partnership in spinal muscular atrophy to address another muscle-wasting disease. For the second time, they’ve arranged an option deal, with milestones built in both before and after licensing.